Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07730281) titled 'PRA-216 COPD Safety and Biomarker Study' on July 23.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Prana Therapies Inc

Condition: Chronic Obstructive Pulmonary Disease (COPD)

Intervention: Drug: PRA-216

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: August 1, 2026

Target Sample Size: 40

To know more, visit https://clinicaltrials.gov/study/NCT07730281

Disclaimer: Curated by HT Syndication....